Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484361 | 0.79 | SSTR4 (0.41) | — | |
| SCHEMBL28106497 | 0.78 | SSTR4 (0.46) | ALDH1A1 | |
| SCHEMBL17697621 | 0.77 | SLC6A3 (0.43) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL30110448 | 0.77 | SSTR4 (0.41) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL390175 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1 | |
| SCHEMBL6014996 | 0.76 | SSTR4 (0.37) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL387472 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL8543691 | 0.70 | SSTR4 (0.42) | — | |
| SCHEMBL18849938 | 0.70 | SLC6A3 (0.46) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL23303999 | 0.70 | CHRNB2 (0.42) | SLC6A3KCNH2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | SLC6A3 328/4885KCNH2 3177/4885TAAR1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.